WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015042497) SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/042497    International Application No.:    PCT/US2014/056702
Publication Date: 26.03.2015 International Filing Date: 21.09.2014
IPC:
C07D 403/14 (2006.01)
Applicants: CALITOR SCIENCES, LLC [US/US]; 107 S. Via El Toro Newbury Park, CA 91320 (US).
SUNSHINE LAKE PHARMA CO., LTD. [CN/CN]; No. 1, Gongye North Road, Northern Industrial Area, Songshan Lake Dongguan, 523808 (CN)
Inventors: XI, Ning; (US).
WU, Weibin; (CN).
FENG, Xuejin; (CN).
WU, Yanjun; (CN)
Agent: XI, Ning; (US)
Priority Data:
61/880,974 22.09.2013 US
61/983,444 23.04.2014 US
Title (EN) SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
(FR) COMPOSÉS D'AMINOPYRIMIDINE SUBSTITUÉE ET PROCÉDÉS D'UTILISATION
Abstract: front page image
(EN)The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the P13K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which P13K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with P13K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
(FR)L'invention concerne la préparation et l'utilisation de nouveaux dérivés d'aminopyrimidine en tant que médicaments candidats sous forme libre ou sous forme de sel pharmaceutiquement acceptable et leurs formulations pour la modulation d'un trouble ou d'une maladie qui est médiée par l'activité des enzymes P13K. L'invention concerne également des compositions pharmaceutiquement acceptables comprenant ces composés et des procédés d'utilisation des compositions dans le traitement de troubles et de maladies, comme des troubles de l'immunité et une inflammation dans lesquels les enzymes P13K jouent un rôle dans la fonction leucocytaire, et des troubles hyperprolifératifs associés à l'activité de P13K, notamment, sans s'y limiter, les leucémies et les tumeurs solides, chez les mammifères, en particulier les humains.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)